Global Superdisintegrants Market Size By Type (Croscarmellose Sodium, Crospovidone), By Application (Oncology, Neurology), By Region, And Segment Forecasts, 2023 to 2032

The Global Superdisintegrants Market was valued at USD 460 million in 2023 and is expected to reach USD 840 million by 2031, growing at a CAGR of 7.6% during the forecast period from 2023 to 2031. Superdisintegrants are critical pharmaceutical excipients that accelerate the disintegration of oral solid dosage forms, enhancing drug bioavailability and therapeutic efficacy. The market's expansion is being driven by the rising demand for fast-dissolving drug formulations, increased prevalence of chronic diseases, and ongoing advancements in drug delivery technologies.

Drivers:

1. Rising Demand for Orally Disintegrating Tablets (ODTs):

ODTs are gaining popularity due to their ease of administration, especially among pediatric and geriatric populations. Superdisintegrants are key to their performance, making them an essential component in modern pharmaceutical formulations.

2. Increase in Chronic Disease Prevalence:

Conditions such as cardiovascular diseases, diabetes, and neurological disorders require long-term medication. The growing demand for rapid-acting and patient-friendly dosage forms is fueling the use of superdisintegrants.

3. Technological Innovations in Drug Formulation:

Pharmaceutical manufacturers are investing heavily in R&D to develop advanced drug delivery systems, where superdisintegrants play a pivotal role in improving patient compliance and treatment outcomes.

Restraints:

1. Regulatory and Quality Compliance Challenges:

Strict regulatory frameworks governing excipient use, along with quality assurance requirements, can delay product approvals and increase costs.

2. Cost Sensitivity in Emerging Markets:

Price-sensitive regions may limit the adoption of high-performance synthetic superdisintegrants, opting for cheaper, less effective alternatives.

Opportunity:

1. Growth in Generic Drug Production:

The surge in generic drug manufacturing across developing regions presents significant opportunities, as superdisintegrants are essential in producing cost-effective, high-quality generics.

2. Increasing Investment in Nutraceuticals and Functional Foods:

The rising integration of superdisintegrants in chewable and rapidly dissolving nutraceuticals opens new avenues for market growth beyond traditional pharmaceuticals.

Market by System Type Insights:

Synthetic Superdisintegrants dominated the market in 2023, driven by their superior performance in terms of swelling capacity, disintegration time, and compatibility with active pharmaceutical ingredients. Examples include sodium starch glycolate, croscarmellose sodium, and crospovidone. These agents are increasingly preferred in high-speed tablet manufacturing due to their reliability and consistency.

Market by End-use Insights:

Pharmaceutical Manufacturers held the largest market share in 2023, leveraging superdisintegrants extensively in prescription and over-the-counter drug formulations. The rise in contract manufacturing and outsourcing among pharmaceutical companies is further propelling the segment. The Nutraceutical Industry is also emerging as a high-growth area, capitalizing on the demand for functional and fast-release health supplements.

Market by Regional Insights:

North America led the global superdisintegrants market in 2023, owing to its robust pharmaceutical manufacturing ecosystem, increasing healthcare expenditure, and high adoption of novel drug delivery systems. Meanwhile, Asia-Pacific is projected to experience the fastest growth through 2031, attributed to the region’s expanding generics market, rising healthcare awareness, and favorable government initiatives to boost pharmaceutical production in countries like India and China.

Competitive Scenario:

Key players in the Global Superdisintegrants Market include Ashland Global Holdings Inc., BASF SE, DuPont, DFE Pharma, JRS Pharma, Roquette Frères, Asahi Kasei Corporation, Avantor, Inc., Corel Pharma Chem, and Dow Chemical Company. These companies are focusing on enhancing their excipient portfolios through product innovations, strategic collaborations, and regional expansions.

Recent Developments Include:

In 2023, BASF introduced a next-generation crospovidone-based superdisintegrant with improved flow properties for high-speed tablet production.

In 2024, Roquette launched a plant-based disintegrant targeting the clean-label pharmaceutical and nutraceutical markets.

In 2025, DFE Pharma expanded its excipient production facility in India to meet growing demand in Asia-Pacific.

Scope of Work – Global Superdisintegrants Market

Key Market Developments:

BASF SE (2023): Launched a novel crospovidone for better compressibility and faster disintegration.

Roquette (2024): Introduced a clean-label natural disintegrant for plant-based formulations.

DFE Pharma (2025): Expanded Asia-Pacific footprint with a new excipient manufacturing unit in India.

FAQs:

1) What is the current market size of the Global Superdisintegrants Market?

The market was valued at USD 460 million in 2023.

2) What is the major growth driver of the Global Superdisintegrants Market?

The primary growth driver is the rising demand for orally disintegrating tablets (ODTs) across therapeutic areas.

3) Which is the largest region during the forecast period in the Global Superdisintegrants Market?

North America is the largest region, while Asia-Pacific is expected to witness the fastest growth.

4) Which segment accounted for the largest market share in the Global Superdisintegrants Market?

The Synthetic Superdisintegrants segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Superdisintegrants Market?

Key players include BASF SE, Ashland, DuPont, DFE Pharma, Roquette, JRS Pharma, and Avantor, Inc.